450 related articles for article (PubMed ID: 26003223)
1. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.
Bayne CE; Williams SB; Cooperberg MR; Gleave ME; Graefen M; Montorsi F; Novara G; Smaldone MC; Sooriakumaran P; Wiklund PN; Chapin BF
Eur Urol; 2016 May; 69(5):775-87. PubMed ID: 26003223
[TBL] [Abstract][Full Text] [Related]
2. Role of radical prostatectomy in metastatic prostate cancer: A review.
Metcalfe MJ; Smaldone MC; Lin DW; Aparicio AM; Chapin BF
Urol Oncol; 2017 Apr; 35(4):125-134. PubMed ID: 28190749
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?
Mathieu R; Korn SM; Bensalah K; Kramer G; Shariat SF
World J Urol; 2017 Apr; 35(4):567-577. PubMed ID: 27502935
[TBL] [Abstract][Full Text] [Related]
4. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
5. Role of surgery in oligometastatic prostate cancer.
Jenjitranant P; Touijer KA
Prostate Int; 2019 Dec; 7(4):125-130. PubMed ID: 31970136
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of cytoreductive prostatectomy in patients with metastatic disease.
Jaber Y; Reichard CA; Chapin BF
Transl Androl Urol; 2018 Sep; 7(Suppl 4):S505-S513. PubMed ID: 30363448
[TBL] [Abstract][Full Text] [Related]
7. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
[TBL] [Abstract][Full Text] [Related]
10. Treatment of the primary in metastatic prostate cancer.
Gîngu C; Heidenreich A; Andreşanu A; Mihancea A; Sinescu I; Baston C
Curr Opin Urol; 2020 Jul; 30(4):566-575. PubMed ID: 32452998
[TBL] [Abstract][Full Text] [Related]
11. The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients.
Moschini M; Soria F; Briganti A; Shariat SF
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):7-11. PubMed ID: 27779202
[TBL] [Abstract][Full Text] [Related]
12. The oncologic role of local treatment in primary metastatic prostate cancer.
Ghadjar P; Briganti A; De Visschere PJ; Fütterer JJ; Giannarini G; Isbarn H; Ost P; Sooriakumaran P; Surcel CI; van den Bergh RC; van Oort IM; Yossepowitch O; Ploussard G
World J Urol; 2015 Jun; 33(6):755-61. PubMed ID: 24997127
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review).
Faiena I; Singer EA; Pumill C; Kim IY
Int J Oncol; 2014 Dec; 45(6):2193-8. PubMed ID: 25340386
[TBL] [Abstract][Full Text] [Related]
14. High-risk prostate cancer: from definition to contemporary management.
Bastian PJ; Boorjian SA; Bossi A; Briganti A; Heidenreich A; Freedland SJ; Montorsi F; Roach M; Schröder F; van Poppel H; Stief CG; Stephenson AJ; Zelefsky MJ
Eur Urol; 2012 Jun; 61(6):1096-106. PubMed ID: 22386839
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive prostatectomy: what is the evidence? A systematic review.
Albisinni S; Aoun F; Diamand R; Al-Hajj Obeid W; Porpiglia F; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2019 Feb; 71(1):1-8. PubMed ID: 30547907
[TBL] [Abstract][Full Text] [Related]
16. Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer.
Cifuentes FF; Valenzuela RH; Contreras HR; Castellón EA
Oncol Rep; 2015 Dec; 34(6):2837-44. PubMed ID: 26503286
[TBL] [Abstract][Full Text] [Related]
17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
18. Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis.
Xiao M; Cong R; Zhang Q; Xiang W; Xiao H
Ann Palliat Med; 2020 May; 9(3):648-660. PubMed ID: 32312070
[TBL] [Abstract][Full Text] [Related]
19. New surgical approaches for clinically high-risk or metastatic prostate cancer.
Dell'Oglio P; Stabile A; Gandaglia G; Zaffuto E; Fossati N; Bandini M; Suardi N; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1013-1031. PubMed ID: 28862047
[TBL] [Abstract][Full Text] [Related]
20. An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer.
Yanagisawa T; Rajwa P; Kawada T; Bekku K; Laukhtina E; Deimling MV; Majdoub M; Chlosta M; Karakiewicz PI; Heidenreich A; Kimura T; Shariat SF
Curr Oncol; 2023 Feb; 30(2):2194-2216. PubMed ID: 36826131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
